Effects of Policosanol and Exercise on Fitness and Lipids in People With Elevated Blood Lipids
Effect of Policosanol Supplementation Combined With Concurrent Exercise Training on Physical Fitness and Lipid Profiles in Healthy Volunteers With Elevated Blood Lipid But Not Required Medical Treatment
This study will evaluate the effects of policosanol supplementation, concurrent exercise training, and their combination on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles in adults with elevated blood lipids who are not currently indicated for lipid-lowering medication.
Participants will be randomly assigned to one of four groups for 12 weeks: policosanol plus exercise training, policosanol alone, placebo plus exercise training, or placebo without structured exercise training. Participants assigned to the supplementation groups will take policosanol 5 mg per day, while those assigned to the placebo groups will take a matching placebo. Participants assigned to the exercise groups will complete a standardized concurrent exercise training program combining aerobic and resistance exercise.
The study will compare changes in physical fitness, lipid profiles, and selected blood biomarkers before and after the intervention. The findings may help determine whether low-dose policosanol, alone or combined with exercise training, can support cardiometabolic health and physical fitness in adults with dyslipidemia.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This clinical trial is designed to examine whether low-dose policosanol supplementation, alone or in combination with concurrent exercise training, can improve physical fitness, muscle recovery, inflammatory responses, and blood lipid profiles in adults with dyslipidemia who are not currently indicated for lipid-lowering medication.
Dyslipidemia is an important modifiable risk factor for cardiovascular disease. Lifestyle modification, including regular exercise, is commonly recommended for individuals with elevated blood lipids before pharmacological treatment is required. Policosanol, a mixture of long-chain aliphatic alcohols mainly derived from plant waxes, has been investigated for its potential effects on lipid metabolism, inflammation, oxidative stress, and exercise-related fatigue. The potential additive effect of combining low-dose policosanol with structured exercise training remains insufficiently established.
This study will compare the independent and combined effects of policosanol supplementation and concurrent exercise training over a 12-week intervention period. The exercise program is designed to integrate aerobic and resistance exercise components. Participants will be assessed at baseline and after the intervention period to determine changes in physical fitness, lipid-related outcomes, and selected biochemical markers related to inflammation and skeletal muscle function.
The study is expected to provide evidence on whether a low dose of policosanol that is regulatory-acceptable (Thai FDA) can be used as an adjunct to exercise training to support cardiometabolic health, physical fitness, and muscle recovery in adults with elevated blood lipid levels. Findings may contribute to future nutrition and exercise recommendations for adults with early-stage dyslipidemia who are not yet receiving lipid-lowering medication.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Nakhon Pathom, Tailandia, 73170
- Institute of Nutrition, Mahidol University
-
Contatto:
- Songdhasn Chinapong, Ph.D.
- Numero di telefono: 435 +66 2 800 2380
- Email: Songdhasn.chi@mahidol.ac.th
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Men and women aged 25 to 59 years.
- BMI between 18.5 and 29.9 kg/m².
- Diagnosed with or presenting with dyslipidemia within the past 3 months, based on laboratory assessment at baseline or a standard laboratory report issued within the past 3 months, according to the National Cholesterol Education Program Adult Treatment Panel III criteria, defined by at least one of the following:
- Total cholesterol ≥ 200 mg/dL;
- Low-density lipoprotein cholesterol ≥ 130 mg/dL and < 190 mg/dL;
- High-density lipoprotein cholesterol < 40 mg/dL in men;
- High-density lipoprotein cholesterol < 50 mg/dL in women;
- Triglycerides ≥ 150 mg/dL.
- Free from chronic or comorbid conditions that contraindicate participation in aerobic or resistance exercise.
- Cleared for physical activity based on the Physical Activity Readiness Questionnaire for Everyone.
- Not regularly physically active during the preceding 3 months, defined as fewer than 3 exercise sessions per week or less than 150 minutes of exercise per week.
- Able and willing to participate in the study procedures and provide written informed consent.
Exclusion Criteria:
- Current or recent use within the past 3 months of lipid-lowering medications or dietary supplements known to influence lipid metabolism, including statins, fibrates, niacin, omega-3 fatty acids, red yeast rice, or policosanol.
- Known allergy or hypersensitivity to policosanol, sugarcane derivatives, capsule components, or any excipients in the supplement formulation.
- Presence of chronic or comorbid conditions that may make exercise participation unsafe, including but not limited to cardiovascular disease, chronic obstructive pulmonary disease, severe arthritis, osteoporosis, uncontrolled diabetes, gastrointestinal disorders, or neurological impairments affecting movement control.
- High-risk lifestyle factors, including heavy smoking, excessive alcohol consumption, or use of recreational drugs.
Inability to comply with the study protocol, including inability to participate in the exercise program when assigned or inability to attend scheduled follow-up assessments.
- Refusal or inability to provide written informed consent independently.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione fattoriale
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Policosanol Plus Exercise Training
Participants in this arm will receive policosanol supplementation at a dose of 5 mg per day for 12 weeks and will participate in a standardized concurrent exercise training program combining aerobic and resistance exercise (3 days per week).
|
Participants assigned to the policosanol intervention will receive policosanol supplementation at a dose of 5 mg per day for 12 weeks.
The supplement will be administered orally.
This intervention is intended to evaluate the effect of low-dose policosanol on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles in adults with dyslipidemia.
Altri nomi:
Participants assigned to the exercise intervention will complete a standardized concurrent exercise training program for 12 weeks.
The program will combine aerobic and resistance exercise components and will be performed 3 days per week, approximately 60 minutes per session.
This intervention is intended to evaluate the effect of structured exercise training, alone or combined with policosanol supplementation, on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles.
Altri nomi:
|
|
Sperimentale: Policosanol Alone
Participants in this arm will receive policosanol supplementation at a dose of 5 mg per day for 12 weeks and will not participate in the structured exercise training program.
|
Participants assigned to the policosanol intervention will receive policosanol supplementation at a dose of 5 mg per day for 12 weeks.
The supplement will be administered orally.
This intervention is intended to evaluate the effect of low-dose policosanol on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles in adults with dyslipidemia.
Altri nomi:
|
|
Comparatore attivo: Placebo Plus Exercise Training
Participants in this arm will receive a matching placebo for 12 weeks and will participate in a standardized concurrent exercise training program combining aerobic and resistance exercise (3 days per week).
|
Participants assigned to the exercise intervention will complete a standardized concurrent exercise training program for 12 weeks.
The program will combine aerobic and resistance exercise components and will be performed 3 days per week, approximately 60 minutes per session.
This intervention is intended to evaluate the effect of structured exercise training, alone or combined with policosanol supplementation, on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles.
Altri nomi:
Participants assigned to the placebo intervention will receive a matching placebo product for 12 weeks.
The placebo will be prepared to resemble the policosanol supplement in appearance and will be administered in the same manner.
This intervention will serve as the control for policosanol supplementation.
|
|
Comparatore placebo: Placebo Alone
Participants in this arm will receive a matching placebo for 12 weeks and will not participate in the structured exercise training program.
|
Participants assigned to the placebo intervention will receive a matching placebo product for 12 weeks.
The placebo will be prepared to resemble the policosanol supplement in appearance and will be administered in the same manner.
This intervention will serve as the control for policosanol supplementation.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Blood Lipid Profile
Lasso di tempo: Baseline, week 6, and week 12
|
Blood lipid profile will be assessed using fasting venous blood samples.
Parameters will include total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides, measured in mg/dL.
Values will be analyzed to determine changes over the 12-week intervention period among the four study groups.
|
Baseline, week 6, and week 12
|
|
Change in Body Mass Index
Lasso di tempo: Baseline, week 6, and week 12
|
Body mass index will be calculated from measured body weight (kg) and height (m) and reported in kg/m².
Change in body mass index will be analyzed from baseline to week 12 among the four study groups.
|
Baseline, week 6, and week 12
|
|
Change in Fat Mass
Lasso di tempo: Baseline, week 6, and week 12
|
Fat mass will be assessed using bioelectrical impedance analysis and reported in kg.
Change in fat mass will be analyzed from baseline to week 12 among the four study groups.
|
Baseline, week 6, and week 12
|
|
Change in Lean Mass
Lasso di tempo: Baseline, week 6, and week 12
|
Lean mass will be assessed using bioelectrical impedance analysis and reported in kg.
Change in lean mass will be analyzed from baseline to week 12 among the four study groups.
|
Baseline, week 6, and week 12
|
|
Change in Physical Fitness
Lasso di tempo: Baseline, week 6, and week 12
|
Physical fitness will be assessed using endurance capacity and muscular strength tests.
Endurance capacity will be evaluated using the YMCA 3-Minute Step Test.
Muscular strength will be assessed using a VALD DynaMo handheld dynamometer, including upper-body grip strength and lower-body isometric strength testing.
Values will be analyzed to determine changes over the 12-week intervention period among the four study groups.
|
Baseline, week 6, and week 12
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Concentration of Interleukin-6 (IL-6)
Lasso di tempo: Baseline, week 6, and week 12
|
Serum interleukin-6 (IL-6) concentration will be measured from fasting venous blood samples and reported in pg/mL to evaluate changes in systemic inflammatory responses following the intervention.
|
Baseline, week 6, and week 12
|
|
Concentration of Tumor Necrosis Factor-alpha (TNF-α)
Lasso di tempo: Baseline, week 6, and week 12
|
Serum tumor necrosis factor-alpha (TNF-α) concentration will be measured from fasting venous blood samples and reported in pg/mL to evaluate changes in systemic inflammatory responses following the intervention.
|
Baseline, week 6, and week 12
|
|
Concentration of Interleukin-10 (IL-10)
Lasso di tempo: Baseline, week 6, and week 12
|
Serum interleukin-10 (IL-10) concentration will be measured from fasting venous blood samples and reported in pg/mL to evaluate changes in anti-inflammatory responses following the intervention.
|
Baseline, week 6, and week 12
|
|
Concentration of Interleukin-1 beta (IL-1β)
Lasso di tempo: Baseline, week 6, and week 12
|
Serum interleukin-1 beta (IL-1β) concentration will be measured from fasting venous blood samples and reported in pg/mL to evaluate changes in systemic inflammatory responses following the intervention.
|
Baseline, week 6, and week 12
|
|
Concentration of Interleukin-1 Receptor Antagonist (IL-1Ra)
Lasso di tempo: Baseline, week 6, and week 12
|
Serum interleukin-1 receptor antagonist (IL-1Ra) concentration will be measured from fasting venous blood samples and reported in pg/mL to evaluate changes in anti-inflammatory responses following the intervention.
|
Baseline, week 6, and week 12
|
|
Concentration of Lactate Dehydrogenase A (LDH-A)
Lasso di tempo: Baseline, week 6, and week 12
|
Serum lactate dehydrogenase A (LDH-A) concentration will be measured from fasting venous blood samples and reported in U/L as a biomarker of muscle tissue response following the intervention.
|
Baseline, week 6, and week 12
|
|
Concentration of Serum Coenzyme Q10
Lasso di tempo: Baseline, week 6, and week 12
|
Serum coenzyme Q10 concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay.
Values will be analyzed to determine changes over the 12-week intervention period among the four study groups reported in µg/mL.
|
Baseline, week 6, and week 12
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MU-CIRB 2026/016.1401
- 4839189 (Altro numero di sovvenzione/finanziamento: Program Management Unit for Competitiveness (PMUC))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Policosanol
-
James Backes, PharmDMarcor Development CorporationCompletatoColesterolo altoStati Uniti